undamentalytics Newsletter
Sign in

Phathom Pharmaceuticals, Inc. insider trading

Every open-market purchase and sale by Phathom Pharmaceuticals, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $0 0 trades by 0 insiders Insider sales, 5 years $7,079 1 trade by 1 insider 3 months later: median +0.6% (−1.5% vs S&P 500)

No insider has bought shares on the open market in five years.

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Phathom Pharmaceuticals, Inc.’s insiders pay?

From March 31, 2020 to July 18, 2025, 11 insiders reported 17 open-market purchases and 20 sales not made under a pre-set plan in Phathom Pharmaceuticals, Inc. Twelve months after each purchase was reported, the shares were +20.9% against the S&P 500 on average (median +25.6%), over 13 purchases with a full year of prices; 62% beat the index. After sales, the shares moved −2.7% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on April 1, 2020 into $27,093 by November 2, 2026, +16.4% a year. It held shares 72% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $29,249 (+17.8% a year), and held throughout $33,602 (+20.3%).

$0$20.0k$40.0k 2020202120222023202420252026 $33.6k$29.2k$27.1k
Copying Phathom Pharmaceuticals, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Phathom Pharmaceuticals, Inc.'s insiders from April 1, 2020, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 72% of the time.
InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Henderson Molly CFO and CBO 0 — — 9 +14.8% (8) April 8, 2025
Curran Terrie President and Chief Executive 2 +22.4% (2) 100% 5 −18.3% (5) January 23, 2025
Parikh Asit Director 7 +29.7% (6) 67% 0 — May 8, 2025
Nabulsi Azmi Chief Operating Officer 2 +7.3% (2) 50% 2 +23.0% (2) January 23, 2025
Topper James N Director 3 — — 0 — May 23, 2025
Takeda Pharmaceutical Co Ltd 10% owner 0 — — 2 −35.8% (2) January 25, 2024
Breedlove Robert Charles Principal Accounting Officer 0 — — 1 +29.2% (1) July 18, 2025
Karbe Frank Director 1 +95.1% (1) 100% 0 — December 16, 2024
Kolchinsky Peter 10% owner 0 — — 1 −82.8% (1) March 15, 2021
Ra Capital Healthcare Fund LP 10% owner 1 −42.2% (1) 0% 0 — April 3, 2020
Ra Capital Management, L.P. 10% owner 1 −17.9% (1) 0% 0 — March 31, 2020

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Phathom Pharmaceuticals, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Phathom Pharmaceuticals, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 4 buying crowds with six months of prices, it averaged +2.5% against the index. After 3 selling crowds, +11.5%. One company's history is too short to judge by; the test across every company is the better guide.

MonthCrowd3 months on, vs S&P 5006 months12 months
January 31, 20253 selling−48.4%+38.7%+114.6%
December 31, 20242 buying−30.2%+0.1%+76.2%
July 31, 20243 selling+40.2%−59.3%−42.9%
March 28, 20243 selling−7.4%+55.0%−60.4%
April 28, 20233 buying+31.7%−18.5%−38.0%
May 31, 20223 buying+21.6%+33.6%+58.3%
April 30, 20202 buying−14.8%−5.3%−32.1%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Phathom Pharmaceuticals, Inc. · Funds · Politicians